Template:Classification of estrogens and antiestrogens by receptor–estrogen complex retention

From blackwiki
Jump to navigation Jump to search

Classification of estrogens and antiestrogens by receptor–estrogen complex retention

Class Examples RE complex retention Pharmacodynamic profile Uterine effects
Short-acting (a.k.a.
"weak" or "impeded")
Template:No selflinkTemplate:No selflinkTemplate:No selflinkTemplate:No selflinkTemplate:No selflinkTemplate:No selflinkTemplate:No selflink Short (1–4 hours) Single or once-daily injections: partial agonist or antagonist Early responsesa
Implant or multiple injections per day: full agonist Early and late responsesb
Long-acting A. Template:No selflinkTemplate:No selflinkTemplate:No selflinkTemplate:No selflinkTemplate:No selflink Intermediate (6–24 hours) Single or once-daily injections: full agonist Early and late responses
B. Template:No selflinkTemplate:No selflinkTemplate:No selflinkTemplate:No selflink Long (>24–48 hours) Single injection: agonist
Repeated injections: antagonist
Early and late responses
Footnotes: a = Early responses occur after 0–6 hours and include water imbibition, hyperemia, amino acid and nucleotide uptake, activation of RNA polymerases I and II, and stimulation of induced protein, among others. b = Late responses occur after 6–48 hours and include cellular hypertrophy and hyperplasia and sustained RNA polymerase I and II activity, among others. Sources: [1][2][3][4][5][6][7]
Template documentation

See also

References

  1. Clark JH, Paszko Z, Peck EJ (January 1977). "Nuclear binding and retention of the receptor estrogen complex: relation to the agonistic and antagonistic properties of estriol". Endocrinology. 100 (1): 91–6. doi:10.1210/endo-100-1-91. PMID 830547.
  2. Clark JH, Hardin JW, McCormack SA (1979). "Mechanism of action of estrogen agonists and antagonists". J. Anim. Sci. 49 Suppl 2: 46–65. doi:10.1093/ansci/49.supplement_ii.46. PMID 400777.
  3. Lunan CB, Klopper A (September 1975). "Antioestrogens. A review". Clin. Endocrinol. (Oxf). 4 (5): 551–72. doi:10.1111/j.1365-2265.1975.tb01568.x. PMID 170029.
  4. Rabe, T.; Runnebaum, B.; Kellermeier-Wittlinger, S. (1994). "Hormontherapie" [Hormone Therapy]. In Benno Runnebaum; Thomas Rabe (eds.). Gynäkologische Endokrinologie und Fortpflanzungsmedizin: Band 1: Gynäkologische Endokrinologie [Gynecological Endocrinology and Reproductive Medicine: Volume 1: Gynecological Endocrinology]. pp. 63–147. doi:10.1007/978-3-662-07635-4_3. ISBN 978-3-662-07635-4.
  5. Clark JH, Markaverich BM (1983). "The agonistic and antagonistic effects of short acting estrogens: a review". Pharmacol. Ther. 21 (3): 429–53. doi:10.1016/0163-7258(83)90063-3. PMID 6356176.
  6. Clark JH, Markaverich BM (April 1984). "The agonistic and antagonistic actions of estriol". J. Steroid Biochem. 20 (4B): 1005–13. doi:10.1016/0022-4731(84)90011-6. PMID 6202959.
  7. Terenius L, Ljungkvist I (1972). "Aspects on the mode of action of antiestrogens and antiprogestogens". Gynecol Invest. 3 (1): 96–107. doi:10.1159/000301746. PMID 4347201.